The GEMSTONE-303 trial, the first Phase III study in China evaluating PD-L1 immunotherapy for advanced GC [13], prospectively enrolled 479 eligible cases meeting the criteria of PD-L1 CPS ≥ 5 in unresectable, locally advanced, or metastatic GC/GEJC, with the primary objective being efficacy assessment of sugemalimab plus capecitabine and oxaliplatin (CAPOX). The gene discussed is CD274; the disease is gastric cancer.